Related Experiment Videos
Role of modelling and simulation in Phase I drug development
L Aarons1, M O Karlsson, F Mentré
1School of Pharmacy, University of Manchester, Manchester, UK.
Summary
Pharmacokinetic/pharmacodynamic modelling and simulation (M&S) is underutilized in Phase I drug development but offers significant value. Addressing implementation barriers can enhance its role in early clinical trials for better decision-making.
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Drug Development
- Clinical Trial Design
Background:
- Pharmacokinetic/pharmacodynamic modelling and simulation (M&S) use has grown in drug development, primarily in patient studies.
- M&S application in Phase I clinical trials, despite a longer history, has not yet achieved comparable impact.
- Emerging trends like biomarker use, clinical trial simulation, and the learn/confirm concept are poised to increase M&S importance in Phase I.
Purpose of the Study:
- To identify the role and advantages of M&S in early clinical drug development.
- To pinpoint obstacles hindering the rational application of M&S in Phase I trials.
- To present expert views on optimizing M&S integration into clinical development.
Main Methods:
- An expert meeting organized by COST B15 in Brussels (January 10-11, 2000) convened to discuss M&S in drug development.
- The article synthesizes the views and opinions expressed by experts during the meeting.
- Analysis of current M&S practices and identification of barriers to its effective use in Phase I.
Main Results:
- M&S is employed in a minority of Phase I trials but serves diverse purposes, including assay limitations, non-linearity characterization, and exposure-response estimation.
- Key applications include sparse sampling, special populations, integrating knowledge for decision-making, simulating Phase II trials, and formulation development.
- Significant impediments to M&S integration include lack of trained personnel, undefined protocols, absence of clear objectives, inadequate resources, and poor quality assurance.
Conclusions:
- M&S holds considerable potential to reshape early clinical trials through improved information extraction and knowledge integration.
- Addressing implementation challenges like training, planning, and resource allocation is crucial for realizing M&S benefits.
- Effective M&S integration can lead to more precise trial outcome predictions and informed decision-making in drug development.